NCT04212091View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

January 18, 2023

Study Completion Date

January 18, 2023

Conditions
HIV Infections
Interventions
BIOLOGICAL

PGT121.414.LS

Administered via IV infusion or SC infusion, depending on the arm

BIOLOGICAL

VRC07-523LS

Administered via IV infusion or SC infusion, depending on the arm

Trial Locations (5)

10032

Columbia P&S CRS, New York

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

90035

UCLA CARE Center CRS, Los Angeles

20037-1894

George Washington Univ. CRS, Washington D.C.

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

collaborator

HIV Prevention Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04212091 - Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants | Biotech Hunter | Biotech Hunter